OSTEX OSTEOMARK BONE RESORPTION ASSAY CLINICALS
This article was originally published in The Gray Sheet
Executive Summary
OSTEX OSTEOMARK BONE RESORPTION ASSAY CLINICALS for monitoring endometriosis patients should complete enrollment by September or October, with a 5 10(k) submission following in December, the Seattle-based biotechnology company says. Initiated in July 1992, the prospective study is enrolling a total of 60-80 pre-menopausal women undergoing gonadotropin-releasing hormone (GnRH) agonist treatment for endometriosis and will include at least three months followup.